investor_relations

Lakewood-Amedex CEO to Present at H.C. Wainwright Conference

Sarasota, Fla. – September 11, 2026 -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026.

CEO Kelvin Cooper to hold one-on-one investor meetings during three-day conference

Kelvin Cooper, Ph.D., chief executive officer of the clinical-stage biotechnology company, will deliver a virtual presentation and conduct one-on-one meetings with registered investors and potential partners. The sessions will cover Lakewood-Amedex's business and clinical development strategy, recent corporate achievements, and anticipated milestones.

U.S. Gold Corp. to Pitch CK Gold Project at Four September Investor Events

Cheyenne, Wyoming – September 11, 2026 -- U.S. Gold Corp. (Nasdaq: USAU) will present its fully permitted CK Gold Project in Wyoming to investors at four separate conferences throughout September 2026, as the company seeks to build market awareness around a recently completed Feasibility Study.

Management targets four investor conferences across three U.S. cities

The company confirmed attendance at the Moody Capital Solutions Disruptive Growth & Life Sciences Conference in New York on September 9-10, followed by the H.C. Wainwright 28th Annual Global Investment Conference in New York from September 14-16. U.S. Gold will then travel to Colorado for the 2026 Precious Metals Summit in Beaver Creek, September 22-25, and Mining Forum Americas 2026 at The Broadmoor in Colorado Springs, September 27-30.

CCOI Investors Face Sept. 21 Deadline in Cogent Fraud Suit

Los Angeles – September 11, 2026 -- Shareholders of Cogent Communications Holdings, Inc. (NASDAQ: CCOI) have until September 21, 2026, to seek lead plaintiff status in a securities fraud class action covering purchases made between February 29, 2024, and May 1, 2026.

Law firm Schall, Brown & Schwartz LLP alleges Cogent misrepresented its optical wavelength order backlog

According to the complaint filed by Schall, Brown & Schwartz LLP ('SBS'), Cogent's stated backlog of orders for optical wavelength products was unlikely to generate revenue because customers in that backlog were unwilling to accept delivery, even where the company was capable of fulfilling orders. The suit alleges the company was not on track to meet its revenue targets and other performance goals throughout the class period, rendering its public statements materially misleading under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.

BPRE Raises Distributions to 7.0%, Sets Oct 6 Roadmap Update

New York – September 10, 2026 -- Bluerock Private Real Estate Fund (NYSE: BPRE) has lifted its distribution rate to 7.0% of net asset value as of June 2026, up from 5.25% at its December 2025 listing, following four separate increases in six months.

Fund schedules October 6 webinar to detail capital rotation progress

BPRE will host a semi-annual progress report webinar on October 6, 2026, at 4:00 p.m. ET titled "BPRE Strategic Roadmap: A Progress Report." Chief Investment Officer Ryan MacDonald and Head of Listed Products Steven Baffico will present updates on the Fund's two-pillar strategy: shifting capital out of legacy core+ institutional real estate holdings into specialty direct property investments, and sustaining distribution growth.

Capricor Therapeutics Faces Securities Fraud Suit Over Deramiocel BLA

Los Angeles – September 10, 2026 -- Schall, Brown & Schwartz LLP (SBS) has issued a reminder to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a securities class action lawsuit alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The lead plaintiff deadline is set for September 28, 2026.

Lawsuit covers CAPR shares purchased between December 17, 2025 and July 26, 2026

The class action targets investors who purchased Capricor shares during this roughly seven-month window. Appointment as lead plaintiff is not a prerequisite for shareholders to participate in any eventual recovery.

Blaize Holdings Faces Securities Fraud Suit Over Revenue Claims

Los Angeles – September 10, 2026 -- Schall, Brown & Schwartz LLP has filed a class action lawsuit against Blaize Holdings, Inc. (NASDAQ: BZAI), alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The lawsuit covers investors who purchased BZAI shares between July 18, 2025 and April 28, 2026, with a lead plaintiff filing deadline set for October 5, 2026.

Complaint alleges Blaize recognized revenue from entities lacking meaningful business activity

According to the complaint, Blaize created an appearance of growth by announcing transactions with counterparties that were not capable of meaningful business operations. The company then improperly recognized revenue from these arrangements, rendering its public statements throughout the class period false and materially misleading, the filing states.

Beta Bionics Faces Securities Fraud Suit Over iLet Pump Disclosures

Los Angeles – September 10, 2026 -- DJS Law Group has reminded shareholders of a class action lawsuit filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The suit covers investors who purchased BBNX shares between July 30, 2025 and February 24, 2026, with a lead plaintiff filing deadline set for November 3, 2026.

Complaint alleges Beta Bionics downplayed FDA findings on its iLet insulin pump

The complaint centers on the iLet Bionic Pancreas insulin pump, Beta Bionics' sole commercialized product. After the company disclosed that the FDA had issued a Form 483 following a manufacturing facility inspection, defendants allegedly told investors the agency's observations were limited to complaint-reporting criteria and did not reflect underlying device problems.

GPGI Faces Securities Fraud Suit Over Husky Acquisition Claims

Los Angeles – September 10, 2026 -- DJS Law Group has issued a reminder to investors of a securities class action lawsuit against GPGI, Inc., formerly known as CompoSecure, Inc. (NYSE: GPGI), with a lead plaintiff deadline set for September 15, 2026.

Lawsuit alleges GPGI misled investors over Husky Technologies deal

The complaint alleges GPGI violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with SEC Rule 10b-5, by making false and misleading statements to the market. According to the filing, GPGI's acquisition of Husky Technologies Limited was structured to benefit related parties and company insiders rather than shareholders.

Regeneron Sued Over Failed Melanoma Trial, $11B Market Cap Loss

San Francisco – September 10, 2026 -- Hagens Berman Sobol Shapiro LLP has filed a securities class action against Regeneron Pharmaceuticals (NASDAQ: REGN) after the failure of a Phase 3 melanoma trial wiped out $11 billion in market capitalization. The suit covers investors who purchased Regeneron shares between August 1, 2025, and May 15, 2026, with a lead plaintiff deadline set for September 14, 2026.

Regeneron's Fianlimab-Libtayo combination failed to hit its primary endpoint

The complaint centers on Regeneron's Phase 3 trial testing Fianlimab combined with Libtayo as a first-line treatment for metastatic or locally advanced melanoma, a therapy management repeatedly called a "potential blockbuster." On May 15, 2026, Regeneron disclosed the trial did not reach statistical significance on its primary endpoint of progression-free survival.

Cogent Communications Hit With Securities Suit Over Wavelength Backlog

San Francisco – September 10, 2026 -- Hagens Berman Sobol Shapiro LLP has filed a securities class action against Cogent Communications Holdings (NASDAQ: CCOI), alleging the company misrepresented its optical wavelength "backlog" as a reliable indicator of revenue growth between February 29, 2024 and May 1, 2026.

Lawsuit targets Cogent's wavelength backlog disclosures as misleading investors

The complaint alleges Cogent's wavelength backlog was largely illusory, with customers unable or unwilling to accept delivery even when the company could provision the wavelengths. Plaintiffs claim this misrepresented actual customer demand and inflated the company's growth narrative.